Zobrazeno 21 - 30
of 449
pro vyhledávání: '"Sai-Hong Ignatius Ou"'
Autor:
Sai-Hong Ignatius Ou, MD, PhD, Joanne Xiu, PhD, Misako Nagasaka, MD, Bing Xia, MD, Shannon S. Zhang, MD, Qing Zhang, PhD, Jeffrey J. Swensen, PhD, David Spetzler, MS, PhD, MBA, Wolfgang Michael Korn, MD, Viola W. Zhu, MD, PhD, Stephen V. Liu, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 2, Pp 100132- (2021)
Introduction: A novel CD74-NRG2α fusion has recently been identified in NSCLC. We surveyed a large tumor database comprehensively profiled by whole transcriptome sequencing to investigate the incidence and distribution of NRG2 fusions among various
Externí odkaz:
https://doaj.org/article/ac0c0482fe5145d4bdb2310e09e643cc
Autor:
Sai-Hong Ignatius Ou, MD, PhD, Yutaka Fujiwara, MD, PhD, Alice T. Shaw, MD, PhD, Noboru Yamamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Frank Fan, MD, Yuki Hao, MSc, Yanfei Gao, MSc, Pasi A. Jänne, MD, Takashi Seto, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 1, Pp 100108- (2021)
Introduction: Taletrectinib (AB-106/DS-6051b) is an oral, potent selective ROS1 and pan-NTRK tyrosine kinase inhibitor (TKI). Preclinically, taletrectinib has activity against ROS1 G2032R solvent-front mutation. Methods: Patients with ROS1+ NSCLC enr
Externí odkaz:
https://doaj.org/article/64233781feae4b948e90754ce61ce9a4
Autor:
Viola W. Zhu, MD, PhD, Misako Nagasaka, MD, Russell Madison, BA, Alexa B. Schrock, PhD, Jean Cui, PhD, Sai-Hong Ignatius Ou, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 1, Pp 100116- (2021)
Lorlatinib is a third-generation ALK inhibitor that can overcome the largest number of acquired ALK resistance mutations, including the solvent-front mutation G1202R. Here, we report, for the first time, a novel, sequentially-evolved EML4-ALK variant
Externí odkaz:
https://doaj.org/article/0f88699f4ca44685b12f532982b48a21
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 3, Pp 100048- (2020)
ROS1 fusion–positive (ROS1+) NSCLC was discovered in 2007, the same year as the discovery of ALK-positive (ALK+) NSCLC but has trailed ALK+ NSCLC in terms of development. There seems to be a differential response to ROS1 inhibitors, which depend on
Externí odkaz:
https://doaj.org/article/370b6835eee34b36bc7ecfc904ba0f15
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 2, Pp 100037- (2020)
Since the discovery of RET fusion–positive (RET+) NSCLC around late 2011 to early 2012, clinical trials of multikinase inhibitors and highly potent and selective RET tyrosine kinase inhibitors have indicated that RET fusion is an actionable oncogen
Externí odkaz:
https://doaj.org/article/4bf386fea8fb4953a9d2f91c6ef4706f
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 1, Pp 100015- (2020)
Since the discovery of anaplastic lymphoma kinase fusion-positive (ALK+) NSCLC in 2007, the methods to detect ALK+ NSCLC have evolved and expanded from fluorescence in situ hybridization and immunohistochemistry to next-generation DNA sequencing, tar
Externí odkaz:
https://doaj.org/article/555bb3db331e4ff1b1172ed1dc9a1871
Autor:
Niki Karachaliou, Imane Chaib, Andres Felipe Cardona, Jordi Berenguer, Jillian Wilhelmina Paulina Bracht, Jie Yang, Xueting Cai, Zhigang Wang, Chunping Hu, Ana Drozdowskyj, Carles Codony Servat, Jordi Codony Servat, Masaoki Ito, Ilaria Attili, Erika Aldeguer, Ana Gimenez Capitan, July Rodriguez, Leonardo Rojas, Santiago Viteri, Miguel Angel Molina-Vila, Sai-Hong Ignatius Ou, Morihito Okada, Tony S. Mok, Trever G. Bivona, Mayumi Ono, Jean Cui, Santiago Ramón y Cajal, Peng Cao, Rafael Rosell
Publikováno v:
EBioMedicine, Vol 29, Iss , Pp 112-127 (2018)
Epidermal growth factor receptor (EGFR)-mutation-positive non-smallcell lung cancer (NSCLC) is incurable, despite high rates of response to EGFR tyrosine kinase inhibitors (TKIs). We investigated receptor tyrosine kinases (RTKs), Src family kinases a
Externí odkaz:
https://doaj.org/article/d4a85629cde14b10a642cf79a55d7f2c
Autor:
Tianhong Li, Patricia LoRusso, Michael L. Maitland, Sai-Hong Ignatius Ou, Erkut Bahceci, Howard A. Ball, Jung Wook Park, Geoffrey Yuen, Anthony Tolcher
Publikováno v:
Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-9 (2016)
Abstract Background ASP3026 is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that has potent in vitro activity against crizotinib-resistant ALK-positive tumors. This open-label, multicenter, first-in-human phase I study ( NCT01284192
Externí odkaz:
https://doaj.org/article/6df78f3e3340454c8deb3c23b520004a
Autor:
Sai-Hong Ignatius Ou
Publikováno v:
Frontiers in Oncology, Vol 4 (2014)
The discovery of anaplastic lymphoma kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC) in 2007 and the approval of crizotinib for the treatment of advanced ALK-rearranged NSCLC in 2011 represents a landmark in the development of target
Externí odkaz:
https://doaj.org/article/88cd174d5c6449499355330935c00077
Autor:
Sai-Hong Ignatius Ou, Jin-Liern Hong, Petros Christopoulos, Huamao M. Lin, Sylvie Vincent, Eric N. Churchill, Junpei Soeda, Daniel Kazdal, Albrecht Stenzinger, Michael Thomas
Publikováno v:
Journal of Thoracic Oncology. 18:744-754